Rapid Microbiology Testing Market By Product (Instruments, Reagents and Kits, and Consumables), By Method (Growth-Based, Viability-Based, Cellular Component-Based, Nucleic Acid-Based, and Other Rapid Microbiology Testing Methods), By Application (Clinical Disease Diagnosis, Food and Beverage Testing, Pharmaceutical and Biological Drug Testing, Environmental Testing, Cosmetic and Personal Care Products Testing, Research Applications, and Other Applications), By End Users, and By Region, and Trends, Analysis And Forecast Till 2034

Rapid Microbiology Testing Market was valued at US$ 5.2 billion in 2024 and is projected to grow at a CAGR of 10.3% to reach US$ 12.7 billion by 2034.

The field of medical science known as microbiology is said to deal with the treatment, diagnosis, and prevention of infectious diseases. When compared to conventional culture-plate procedures, rapid microbiology testing methods, also known as microbiological methods, are useful for obtaining microbiology test results more quickly.

Increasing concerns about food safety are a key factor driving the market's expansion. Rising adoption of microbiology testing for the diagnosis of infectious diseases in humans, rising funding, research grants, and public-private investments, rising emphasis on accurate and early disease diagnosis, rising research activities and rising the number of infection diseases has also become the major contribution in Rapid Microbiology Testing Market growth. In addition, increasing government initiatives for the detection of antimicrobial resistance, increasing emerging countries and rising bioterrorism surveillance will further boost the growth of Rapid Microbiology Testing Market.

                   For More Report Details, Download Free Sample PDF

The growing incidence of infectious diseases and technological advancements to boost market growth

There is a growing understanding of the need of early infection detection to reduce risk. It is accelerating the expansion of the microbiology testing market. As infectious diseases are spreading around the globe, both the government and non-governmental organizations support innovative technology in clinical microbiology. Clinical microbiology employs a variety of fast assays to quickly diagnose infections in critical situations by detecting specific microbial antigens or nucleic acids in primary non-tissue materials are also contributing in the growth of Microbiology Testing Market.

For instance, in 2019, according to The Centers for Disease Control and Prevention (CDC), number of tuberculosis cases are 8,916, number of new salmonella case are 58,371, number of new Lyme disease cases are 34,945 and number of new meningococcal disease cases are 371.

Furthermore, In November 2022, IDEXX, a global leader in rapid microbiology testing for water acquired Tecta-PDS, an innovative Canadian company has introduced automation to water microbiology testing for parameters including E. coli and total coliforms. The acquisition promotes the expanding of water microbiology testing options for both laboratory-based and in-field testing. It has been approved and accepted by regulatory agencies in over 40 countries.

The rise in food safety concerns

The components of an individual food product are plants and animals, and they often contain a variety of microbes. During the production and consumption processes, natural microbes may come into contact with food and contaminate it. Additionally, microbial contamination of food products leads to deterioration, which, if consumed, can result in foodborne diseases. Around the world, foodborne infections are considered to be severe public health problems. The importance of food safety as a measure to prevent the spread of diseases is the factor that boost the growth of Microbiology Testing Market.

For instance, according to The Centers for Disease Control and Prevention (CDC), it is estimated that each year 1 in 6 Americans get sick from contaminated food or beverages and 3,000 die from foodborne illness. The U.S. Department of Agriculture (USDA) estimates that foodborne illnesses cost the United States more than $15.6 billion each year.

Restrains:

Clinical microbiology requires a knowledgeable and well-trained team since pathogenic microbes must be dealt with. The test's equipment is high tech and challenging to handle, which is estimated to hamper the growth of the Rapid Microbiology Testing Market. The rise in technical issues in real-time is also hindering the demand of the market. Strict rules by the government in approval of new products are further expected to impede the market’s growth.

Rapid Microbiology Testing Market is segmented based on Product, Method, Application, End-Users and Region.

Product Insight

On the basis of Product, Rapid Microbiology Testing Market is segmented into Instruments, Reagents and Kits, and Consumables. Instruments segment is expected to dominate the target market growth due to the growing prevalence of infectious diseases and cancer, increased funding for R&D, and technological advancements. Expanding testing volume, rapid and accurate result among others, rising demand for instruments that offer automation and high-throughput capabilities to process a large number of samples in a shorter period of time are anticipated to grow this segment.

Method Insights

On the basis of Method, Rapid Microbiology Testing Market is segmented into Growth-Based, Viability-Based, Cellular Component-Based, Nucleic Acid-Based, and Other Rapid Microbiology Testing Methods. Growth-Based segment are expected to dominate the target market growth as it can provide a quantitative cell count, an estimation of viable cell concentration, information about the presence of a specific microorganism, or microbial identification. The early detection of infectious diseases, growing R&D investments to develop new rapid diagnostic kits, increased adoption of rapid Point of care (POC) diagnostic tests for diagnosing disease like COVID-19 are the factors that fuel the growth of this segment.

Application Insights

On the basis of Application, Rapid Microbiology Testing Market is segmented into Clinical Disease Diagnosis, Food and Beverage Testing, Pharmaceutical and Biological Drug Testing, Environmental Testing, Cosmetic and Personal Care Products Testing, Research Applications, and Other Applications. Pharmaceutical and Biological Drug Testing segment are expected to dominate target market growth due to the presence of well-established and globally accepted regulation that govern the evaluation of microbial contamination during pharmaceuticals manufacturing and raw material sourcing. The growing volume of pharmaceuticals drugs manufactured across the globe is another factor that drives the growth of this segment.

End-Users Insights

On the basis of End-Users, Rapid Microbiology Testing Market is segmented into Diagnostic Laboratories and hospitals, Food and Beverage Companies, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Other End Users. The Diagnostic Laboratories and Hospitals segment are expected to dominate the target market growth due to the factors such as increasing prevalence of infectious diseases, improving healthcare expenditure, early disease diagnosis, the introduction of advanced, accurate, and rapid methods for faster clinical diagnosis.

Regional Insights:

On the basis of region, the Rapid Microbiology Testing Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to factors such as increasing technological advancements that make microbiology tests faster, cheaper and more accurate. The rising burden of infectious diseases and outbreaks of epidemics, well-established healthcare infrastructure and increasing healthcare spending are anticipated to increase demand for Rapid Microbiology Testing in the region.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Rapid Microbiology Testing Market report based on Product, Method, Application, End-Users and Region:

Rapid Microbiology Testing Market, By Product:

• Instruments
• Reagents and Kits
• Consumables

Rapid Microbiology Testing Market, By Method:

• Growth-Based
• Viability-Based
• Cellular Component-Based
• Nucleic Acid-Based
• Other Rapid Microbiology Testing Methods

Rapid Microbiology Testing Market, By Application:

• Clinical Disease Diagnosis
• Food and Beverage Testing
• Pharmaceutical and Biological Drug Testing
• Environmental Testing
• Cosmetic and Personal Care Products Testing
• Research Applications
• Other Applications

Rapid Microbiology Testing Market, By End-Users:

• Diagnostic Laboratories and hospitals
• Food and Beverage Companies
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Other End Users

Rapid Microbiology Testing Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

he key players operating the Rapid Microbiology Testing Market includes, Abbott Laboratories, Becton Dickinson and company, BioMerieux S.A., Bruker corporation, Charles River Laboratories, Danaher corporation, Don whitley Scientific limited, Merck KGAA, Neogen corporation, Quidel Corporatio, and Rapid Micro Biosystems.

Recent Development:

• In July 2020, bioMérieux, a world leader in the field of in vitro diagnostics, announced the launch of ‘BIOFIRE® MYCOPLASMA’. It is an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies). BIOFIRE® MYCOPLASMA is an innovative, rapid and very easy-to-use molecular biology test because the DNA extraction, amplification and detection steps are fully automated and may be performed outside of the laboratory by nearly anyone after simple training.
• In April 2022, Hygiena™, a company that delivers rapid microbial detection, monitoring, and identification solutions to a wide range of industries, including food and beverage, health care, hospitality, pharmaceuticals, and personal care announced the launch of new ultra-rapid microbial screening kit known as “The RapiScreen Beverage Kit”. It provides quality control results in less than 30 minutes following a preliminary incubation period and allowing manufacturers to confirm product quality for quick release to market. The new system reduces product hold time from 4-10 days to 1-2 days, eventually improving inventory turn and cash flow.

• Abbott Laboratories*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Becton Dickinson and company
• BioMerieux S.A.
• Bruker corporation
• Charles River Laboratories
• Danaher corporation
• Don whitley Scientific limited
• Merck KGAA
• Neogen corporation
• Quidel Corporatio
• Rapid Micro Biosystems.

“*” marked represents similar segmentation in other categories in the respective section.